Matthew L Sherman Deciphera Pharmaceuticals, Inc. (DCPH) insider trading activity

Matthew L Sherman is EVP & Chief Medical Officer of Deciphera Pharmaceuticals, Inc.. Currently has a direct ownership of 0 shares of DCPH, which is worth approximately $0. The most recent transaction as insider was on Jun 11, 2024, when has been sold 72,261 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

Matthew L Sherman Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 11 2024	SELL Disposition due to a tender of shares in a change of control transaction	-	72,261 Reduced 100.0%	0 Common Stock
Jun 11 2024	SELL Sale (or disposition) back to the issuer	-	72,029 Reduced 49.92%	72,261 Common Stock
Jun 11 2024	BUY Grant, award, or other acquisition	-	34,157 Added 19.14%	144,290 Common Stock
Feb 16 2024	SELL Open market or private sale	$40,846 $15.62 p/Share	2,615 Reduced 2.35%	108,739 Common Stock
Feb 15 2024	BUY Grant, award, or other acquisition	-	17,275 Added 13.43%	111,354 Common Stock
Jan 16 2024	SELL Open market or private sale	$35,234 $14.47 p/Share	2,435 Reduced 2.52%	94,079 Common Stock
Dec 13 2023	SELL Open market or private sale	$42,913 $15.37 p/Share	2,792 Reduced 2.81%	96,514 Common Stock
Dec 12 2023	BUY Grant, award, or other acquisition	-	8,244 Added 7.67%	99,306 Common Stock
Oct 30 2023	SELL Open market or private sale	$28,367 $12.02 p/Share	2,360 Reduced 2.54%	90,628 Common Stock
Oct 28 2023	BUY Grant, award, or other acquisition	-	8,244 Added 8.14%	92,988 Common Stock
Oct 02 2023	SELL Open market or private sale	$37,304 $12.68 p/Share	2,942 Reduced 3.36%	84,744 Common Stock
Jun 16 2023	SELL Open market or private sale	$23,832 $14.4 p/Share	1,655 Reduced 1.85%	87,686 Common Stock
Feb 16 2023	SELL Open market or private sale	$14,662 $15.1 p/Share	971 Reduced 1.09%	88,145 Common Stock
Feb 15 2023	BUY Grant, award, or other acquisition	-	16,488 Added 15.61%	89,116 Common Stock
Jan 17 2023	SELL Open market or private sale	$51,039 $21.24 p/Share	2,403 Reduced 3.2%	72,628 Common Stock
Oct 03 2022	SELL Open market or private sale	$48,455 $18.73 p/Share	2,587 Reduced 3.36%	74,297 Common Stock
Jun 16 2022	SELL Open market or private sale	$19,006 $10.75 p/Share	1,768 Reduced 2.25%	76,884 Common Stock
Feb 16 2022	SELL Open market or private sale	$8,905 $9.05 p/Share	984 Reduced 1.27%	76,790 Common Stock
Jan 18 2022	BUY Grant, award, or other acquisition	-	20,500 Added 20.86%	77,774 Common Stock
Dec 15 2021	BUY Grant, award, or other acquisition	-	11,100 Added 16.23%	57,274 Common Stock
Oct 04 2021	SELL Open market or private sale	$88,199 $33.17 p/Share	2,659 Reduced 5.46%	46,029 Common Stock
Feb 16 2021	SELL Open market or private sale	$6,451 $48.87 p/Share	132 Reduced 0.35%	37,286 Common Stock
Feb 16 2021	BUY Grant, award, or other acquisition	-	11,100 Added 18.66%	48,386 Common Stock
Dec 09 2020	BUY Exercise of conversion of derivative security	$7,127 $34.43 p/Share	207 Added 0.55%	37,418 Common Stock
Nov 16 2020	BUY Exercise of conversion of derivative security	$92,858 $34.43 p/Share	2,697 Added 6.76%	37,211 Common Stock

Also insider at

PIRS

PIERIS PHARMACEUTICALS, INC. Healthcare

Director

MLS